Key result
Hesperidin administration significantly reduced systolic blood pressure (SMD -0.86) and total triglycerides compared to placebo or control.
Why the study?
Recently published clinical studies prompted an updated systematic review and meta-analysis to evaluate the beneficial effects of hesperidin on cardiovascular parameters.
Does hesperidin reduce blood pressure and improve lipid profiles in subjects with cardiovascular or metabolic disorders?
Meta-Analysis (n=2,414)
Does hesperidin reduce blood pressure and improve lipid profiles in subjects with cardiovascular or metabolic disorders?
Standardized Mean Difference: -0.86 (95% CI -1.53–-0.18)
p-value: p=0.01
Hesperidin supplementation may serve as a beneficial adjuvant therapy for reducing systolic blood pressure and total triglycerides in patients with cardiovascular risk factors.
Hesperidin supplementation improves lipids and SBP; extends 2019 meta-analysis with recent RCTs.
Abstract Background The cardioprotective activity of hesperidin has been well demonstrated in several clinical studies. Also, there is a meta-analysis published on this topic in 2019. However, considering the recently published clinical studies there is a scope for performing a systematic review and meta-analysis on the cardioprotective effect of hesperidin. This systematic review and meta-analysis were performed to determine the beneficial effect of hesperidin in alleviating alterations in cardiovascular parameters based on available clinical studies. Methods The literature search was performed using online databases such as PubMed and Google Scholar. The search was mainly focused on the role of hesperidin in various cardiovascular disorders. Results Based on the inclusion and exclusion criteria 9 clinical studies involving 2414 subjects were included. The meta-analysis revealed that the hesperidin has significantly reduced the systolic blood pressure (Inverse variance (I.V): -0.86 (-1.53 to -0.18) at 95% CI, p = 0.01, I2 = 100%) and total triglycerides (IV: -0.21 (-0.40 to -0.02) at 95% CI, p = 0.03, I2 = 12%). However, there were no statistically significant changes in the diastolic blood pressure (IV: 0.52 (-1.78 to 2.83) at 95% CI, p = 0.06, I2 = 100%), HDL (IV: 0.04 (-0.25 to 0.34) at 95% CI, p = 0.78, I2 = 56%), LDL (IV: -0.10 (-0.66 to 0.45) at 95% CI, p = 0.72, I2 = 85%), and total cholesterol (TC) (IV: 0.18 (-0.79 to 0.44) at 95% CI, p = 0.57, I2 = 88%) compared with the placebo/control. Conclusion The outcomes of the meta-analysis suggest that hesperidin administration could benefit patients with cardiovascular diseases by reducing systolic blood pressure and total triglycerides.
No takes yet. Share an insight, caveat, or question.
Shylaja et al. (2023) conducted a meta-analysis in Cardiovascular diseases and metabolic disorders (n=2,414). Hesperidin vs. Placebo/control was evaluated on Systolic blood pressure (SMD -0.86, 95% CI -1.53 to -0.18, p=0.01). Hesperidin administration significantly reduced systolic blood pressure (SMD -0.86) and total triglycerides compared to placebo or control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: